All articles by GlobalData Healthcare

Emergent seeking to reverse fortunes and become a major overdose treatment player

Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose treatment portfolio, which…
FDA review designations: tracking 40 years of innovation

Regulatory authorities play a pivotal role in accelerating, encouraging and incentivising the development and approval of novel treatments via the…
FDA’s START and CoGenT pilot programmes: Streamlining rare disease drug approvals

This week, at the J.P. Morgan Healthcare Conference and the Biotech Showcase, discussions underscored the growing focus on innovation in…
Interleukin inhibitors remain a strong growth driver in dermatology

As companies across the pharma and biotech sectors gathered at the annual JPM Healthcare Conference 2025, held from 13 January…
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy

Approaching his 200th day as the new Chief Executive Officer of Lonza, Wolfgang Wienand discussed the company’s plans to exit…

Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?

The first day of the JP Morgan Healthcare Conference held in San Francisco, California from 13 January to 15 January…
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth

The chronic obstructive pulmonary disease (COPD) market continues its trajectory of rapid growth, bolstered by significant advancements in biologics and…
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player…
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance

Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is characterised by progressive muscle degeneration and weakness, and is…
Aggressive protection of Stelara may indicate J&J’s immunology strategy

During its presentation at the JP Morgan Healthcare Conference 2025, Johnson and Johnson (J&J) suggested it would undertake an aggressive…

Sections